The Association Between Breast Cancer Prognostic Indicators and Serum 25-OH Vitamin D Levels
Annals of Surgical Oncology, 04/05/2012
Peppone LJ et al. – Breast cancer (BC) patients with a more aggressive molecular phenotype (basal–like) and worse prognostic indicators (ER- and triple–negative) had lower mean 25–OH vitamin D levels. Further research is needed to elucidate the biological relationship between vitamin D and BC progression.Methods
- 25–OH vitamin D levels were collected from 194 women who underwent BC surgery and 194 cancer–free (CF) controls at the University of Rochester between January 2009 and October 2010.
- Mean 25–OH vitamin D levels and odds ratios (OR) were calculated by case/control status for the overall cohort and by prognostic indicators (invasiveness, ER status, triple–negative status, Oncotype DX score, molecular phenotype) for BC cases.
- BC cases had significantly lower 25–OH vitamin D levels than CF controls (BC: 32.7 ng/mL vs. CF: 37.4 ng/mL; P = .02).
- In case–series analyses, women with suboptimal 25–OH vitamin D concentrations (<32 ng/mL) had significantly higher odds of having ER- (OR = 2.59, 95% confidence interval [95% CI] = 1.08–6.23) and triple–negative cancer (OR = 3.15, 95% CI = 1.05–9.49) than those with optimal 25–OH D concentrations.
- Women with basal–like phenotype had lower 25–OH vitamin D levels than women luminal A phenotype (basal–like: 24.2 ng/mL vs. luminal A: 32.8 ng/mL; P = 0.04).